4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
AgomAb Therapeutics NV (AGMB) operates in the Biotechnology industry and is headquartered in Antwerp, Belgium with about 62 employees. Its market capitalization is roughly $616 million. In the fiscal year ended 2025-12-31, AGMB reported $0M in revenue and ($62M) in net income.
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($59M) | ($48M) | ($31M) | ($23M) |
| Net Income | ($62M) | ($46M) | ($11M) | ($8M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | $0M | $0M |
| Operating Income (EBIT) | ($16M) | ($12M) |
| Net Income | ($17M) | ($12M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $154M | $206M | $171M | $101M | — |
| Total Liabilities | $23M | $18M | $20M | $35M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AGMB viewer.
About TickerBase · Data methodology & sources